Core Viewpoint - Embla Medical has signed an agreement to acquire a 51% majority share in Streifeneder ortho.production GmbH, enhancing its position in the global orthopaedic market and expanding its product offerings [1][3]. Company Overview - Embla Medical is a leading global provider of innovative mobility solutions, with a mission to improve people's mobility and a workforce of over 4,000 employees [10]. - Streifeneder ortho.production GmbH is an international developer and supplier of orthopaedic mobility solutions, employing around 100 people and generating sales of EUR 25 million (approximately USD 29 million) in 2024 [2][10]. Market Position and Growth Potential - The investment allows Embla Medical to become a full-range provider in the global orthopaedic and prosthetics (O&P) market, particularly strengthening its presence in Germany, the second largest O&P market globally [3][5]. - Streifeneder is expected to grow in line with the global prosthetics market, projected to increase by 5-7% in the near term [3]. Financial Details - The transaction involves the issuance of 2,805,135 new shares at a price of DKK 33.26 each, raising DKK 93 million (EUR 12.5 million) in total share capital [6]. - The financial impact of the transaction is not expected to materially affect Embla Medical's financial guidance for 2025 [8]. Strategic Fit - The acquisition aligns with Embla Medical's Growth'27 strategy, enabling the company to reach more patients and expand its product offerings [5]. - The combination of Embla Medical and Streifeneder is anticipated to enhance customer experience and secure a leading position in the O&P market [6].